Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice (Q43997002)

28 November 2017

title

Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice (English)

1 reference

28 November 2017

0 references

L F van der Voort

1

1 reference

28 November 2017

A Kok

2

1 reference

28 November 2017

A Visser

3

1 reference

28 November 2017

C B M Oudejans

4

1 reference

28 November 2017

M Caldano

5

1 reference

28 November 2017

F Gilli

6

1 reference

28 November 2017

A Bertolotto

7

1 reference

28 November 2017

C H Polman

8

1 reference

28 November 2017

J Killestein

9

1 reference

28 November 2017

publication date

19 September 2008

1 reference

Multiple Sclerosis Journal

28 November 2017

published in

1 reference

28 November 2017

volume

15

1 reference

28 November 2017

issue

2

1 reference

28 November 2017

page(s)

212-218

1 reference

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096877

Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096877

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096877

Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096877

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096877

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096877

Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096877

Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096877

Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096877

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096877

Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096877

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096877

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096877

Neutralising antibodies to interferon beta during the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096877

Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096877

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096877

21 January 2018

Identifiers

DOI

10.1177/1352458508096877

1 reference

28 November 2017

1 reference